Crossbow Therapeutics is focused on advancing cancer treatment through the development of innovative antibody therapeutics that target a wide array of cancer antigens. Their approach involves identifying and validating promising cancer antigens to create T-Cell Receptor mimetics (TCRm). These TCRm antibodies are designed to mimic the function of natural T-Cell Receptors, allowing for precise targeting of tumor-specific peptides presented by Major Histocompatibility Complex (MHC). This technology aims to enhance the efficacy of immunotherapy by improving the accuracy and potency of the therapeutic agents.

The company utilizes a proprietary technology engine to produce high-quality TCR-mimetics, which are then integrated into T-Cell engagers and other immunotherapeutic products. This innovative design not only optimizes manufacturability but also aims to minimize the potential for tumor resistance, thereby broadening the therapeutic impact of their treatments. Crossbow Therapeutics is committed to revolutionizing cancer care by expanding the reach of antibody-based therapies and improving the lives of patients through their cutting-edge research and development efforts.

United States

Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.

Crossbow Therapeutics

Company Details